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Introduction
Immune responses are initiated in secondary lymphoid tissues (SLT), where naive T cells encounter antigens 
presented by DCs (1). DCs are conventional antigen-presenting cells (APCs) and play an essential role in the 
activation and differentiation of T cells (2). The expression of positive costimulatory molecules CD80 and CD86 
by DCs is critical to the effective activation of naive T lymphocytes (1, 3). Negative costimulatory molecules 
such as programmed cell death protein 1 (PD-1), on the contrary, limit the activity of proinflammatory T cells by 
decreasing their proliferation and ability to produce cytokines, promoting anergy or apoptosis, and potentiating 
the activity of Tregs (4). The enhancement of the activity of PD-1 has been associated with the attenuation of  
T cell–mediated immune diseases (5), and its antagonism has been shown to increase antitumor immunity (6).
Antibody-mediated blockade of  PD-1 promotes the conversion of  anergic T cells into functional 
effector T cells, facilitating the antitumor immune response (7–9). Though the development of  immune 
checkpoint inhibitors has advanced the field of  immunotherapy significantly, the efficacy of  these inhibitors 
requires improvement. For instance, solitary treatment with the anti–PD-1 mAb nivolumab was found 
to confer an overall survival rate of  only about 50% over 3 years (10). Furthermore, the onset of  toxicity 
in patients and a steady increase in its incidence are causes for concern (11). Nearly 21% of  patients 
treated with nivolumab develop treatment-related adverse effects (10). A broad range of  treatment-related 
adverse events occur with PD-1 pathway blockade, including liver and pancreatic toxicity, inflammatory 
pneumonitis, and interstitial nephritis, all of  which may be fatal (12, 13). These toxicities are attributable 
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to immune overactivation (14, 15). Lastly, the high-dose of  anti–PD-1 mAb required for a therapeutic 
outcome substantially increases the cost of  treatment (10).
Enhancing the efficacy of  checkpoint inhibitors has been the focus of  many research efforts, including, 
for example, use of  biomaterial-based delivery systems such as hydrogels (16), microneedle patch–assisted 
delivery (17), and nanoparticles (NPs) (18–20).
NPs offer numerous advantages, including the improvement in pharmacokinetics and biodistribution 
of  therapeutics, enhancement of  tissue penetration and intracellular delivery capacity, and site-specific 
accumulation of  systemically administered therapeutics (21, 22). An additional advantage of  using NPs is 
the minimization of  the treatment cost, due to the use of  a lower dose of  anti–PD-1.
A practical target of  NP-based drug delivery would be the spleen, considering it is a key SLT populated 
with APCs that are capable of  presenting antigens efficiently to resident T cells, thereby activating them 
(23). These T cells can then migrate to areas of  injury, including tumor sites (24, 25). Due to the action of  
resident myelosuppressive immune cells, the splenic environment can also produce immune tolerance (26). 
The spleen, thus, becomes a rational target of  which the manipulation could shift the immune response 
toward a state of  activation, thereby enhancing the antitumor efficacy of  immune checkpoint inhibitors 
(27–29). Here, we show that delivery of  anti–PD-1 to the spleen via NPs results in a potent antitumor 
response. Our data show that, despite the use of  a low dose of  anti–PD-1, delivery of  the antibody via NPs 
results in the maintenance of  significant antineoplastic efficacy.
Results
Characterization of  anti–PD-1 NPs. PLGA, a biodegradable and biocompatible synthetic polymer approved 
for clinical use by the US Food and Drug Administration (FDA), was used to encapsulate anti–PD-1 mAb 
into NPs (Figure 1A). These anti–PD-1 NPs had a well-defined spherical shape and uniform structure, as 
depicted in the transmission electron micrograph (Figure 1B). Dynamic light scattering demonstrated that 
the average hydrodynamic size of  anti–PD-1 NPs was about 150 nm with the polydispersity index (PDI) 
of  about 0.2 (Figure 1C). Release kinetics of  anti–PD-1 NPs was determined by incubation at 37°C in 
an orbital incubator shaker and by measuring the released anti–PD-1 mAb by ELISA using recombinant 
PD-1–coated (rPD-1–coated) plates. Antibody molecules were released from the NPs in a sustained manner 
over 2 weeks, and their affinity for PD-1 remained preserved throughout this duration (Figure 1D and Sup-
plemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.122700DS1). An encapsulation efficacy of  26.2% ± 3% was achieved. Low-dose and high-dose 
anti–PD-1 NPs contained, respectively, ~1.8 μg and ~3.6 μg anti–PD-1 mAb per 100 μl of  NPs suspension.
The capacity of  anti–PD-1 NPs to promote activation of  T cells was evaluated using an allogeneic mixed 
lymphocyte reaction (MLR) assay. As shown in Figure 1E, anti–PD-1 NP–treated DCs induced prolifera-
tion of  T cells more robustly than untreated DCs or DCs treated with anti–PD-1 or empty NPs. Flow cyto-
metric analysis demonstrated that this difference in the behavior of  anti–PD-1 NP–treated DCs correlated 
with a higher expression of  positive costimulatory molecules CD40, CD80, and CD86 (Figure 1, F–H). DCs 
could potentially release anti–PD-1 mAb following the uptake of  NPs. To assess this possibility, we incubat-
ed isolated splenic DCs with APC-labeled anti–PD-1 NPs for 1 hour. Following the incubation, DCs were 
washed and cultured with T cells for 6 hours. Next, the T cells were analyzed by flow cytometry to assess for 
the presence of  labeled anti–PD-1 mAb in T cells. A high percentage of  expression of  fluorochrome APC 
in CD4+ T cells, labeled with the fluorochrome APC, was observed in the group that was coincubated with 
DCs that were precultured with APC-labeled anti–PD-1 NPs. As expected, the vehicle-treated group did not 
contain CD4+ T cells that expressed the fluorochrome APC (Supplemental Figure 1B).
Next, we assessed the trafficking of  NPs to melanoma tumor by i.v. injecting fluorescently labeled NPs 
(IR800 NPs) into B16-F10 melanoma tumor–bearing mice followed by live imaging. The NPs immediately 
distributed throughout the mouse, localized to the tumor at the early time point, and were cleared by 24 
hours (Figure 2A). Ex vivo images confirmed that the NPs were not retained indefinitely in the tumor, 
though they were present in the spleen at 24 hours after injection (Figure 2B). Immunofluorescence staining 
of  splenocytes incubated with NPs for 3 hours showed that the fluorescently labeled NPs were explicitly 
internalized by CD11c+, F4/80+, and CD11b+ cells (Figure 2C). Then, we examined the uptake of  fluo-
rescently labeled NPs (CF660 NPs) by splenic CD11c+, F4/80+, and CD11b+ cells following i.v. injection. 
Cytometric analysis of  splenocytes 24 hours following injection of  NPs showed that NPs were internalized 
by the CD11c+ DCs, F4/80+ macrophages, and CD11b+ myeloid cells (Figure 2D).
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Figure 1. Characterization of anti–PD-1 NPs in vitro. (A) Schematic illustration of anti–PD-1 loaded in PLGA NPs. (B) Representative TEM image of 
anti–PD-1 NPs, negatively stained, imaged at 80.0 kV (scale bar: 100 nm) revealing uniform spherical shape of NPs. (C) Size distribution of anti–
PD-1 NPs, as measured by DLS, showing the hydrodynamic size of NPs to be 158.3 (±4.2) nm. (D) Release kinetics of anti–PD-1 mAb from PLGA NPs 
revealing sustained release of anti–PD-1 mAb over time with activity maintained for 2 weeks. Data are mean ± SEM of 3 preparations. (E) Anti–PD-1 
NPs enhanced T cell proliferation. After an incubation period of 24 hours (hr), CD11c+ DCs were washed with DPBS, and allogeneic CD3+ T cells were 
added to these cells. The cells were incubated together for 48 hr at 37°C in a humidified atmosphere containing 5% CO2. The cells were labeled with 
[3H]-Thymidine (0.25 μCi per well) for an additional 16 hr to measure T cell proliferation. [3H]-Thymidine incorporation results show significant prolif-
eration responses to anti–PD-1 NPs in comparison with control, free anti–PD-1 (anti–PD-1), and empty NPs. CPM, counts per minute. (F–H)Represen-
tative images and bar graphs show median fluorescence intensities for (F) CD40, (G) CD80, and (H) CD86 among CD11c+ DCs. Data represent mean ± 
SEM. **P<0.01; ***P<0.005 calculated by 1-way ANOVA.
4insight.jci.org   https://doi.org/10.1172/jci.insight.122700
R E S E A R C H  A R T I C L E
Figure 2. In vitro and in vivo distribution and retention of NPs in melanoma tumor-bearing mice. (A) Representative images of the distribution of 
IR800 NPs in a melanoma tumor–bearing mouse from 1 minute to 24 hr showing accumulation of NPs at the tumor site. By the 24-hr mark, the NPs 
are no longer observed. (B) Representative images and quantitative fluorescence intensities of tumors and spleens as calculated from ex vivo images 
0 hr (before injection), 6 hr, and 24 hr after administration. The data shown are mean ± SEM (n = 3–4 mice/group). (C) Micrograph of splenocytes 
illustrating localization of NPs within the cytoplasm following 3 hr of incubation in vitro with NPs. Intracellular fluorescence intensities were detect-
ed by confocal microscopy. (D) Uptake of CF660 NPs by APCs in the spleens harvested from melanoma tumor–bearing mice 24 hr following injection, 
as measured by flow cytometry. Data represent mean ± SEM (n = 3 mice/group). Statistical significance was calculated using 1-way ANOVA (B) and 
2-tailed Student’s t test (D). *P<0.05; **P<0.01; ***P<0.005.
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Administration of  high-dose anti–PD-1 NPs results in significant T cell activation and death. WT (C57BL/6 WT) 
mice were treated every other day with anti–PD-1 NPs (3.6 μg anti–PD-1 mAb per 100 μl of  NPs injection/
mouse) for the lifespan of the study. This group of mice was referred to as the high-dose group, and their overall 
survival was monitored. Unexpectedly, we found that ~70% of C57BL/6 WT mice (5 of 7 treated mice) expe-
rienced death within 2 weeks of treatment. On the contrary, mice treated with empty NPs or anti–PD-1 (60 μg 
per injection/mouse) using the same protocol as above showed no mortality during 1 month of observation.
We hypothesized that immune overactivation played a role in the death of  mice treated with high-dose 
anti–PD-1 NPs. Compared with naive mice and mice treated with anti–PD-1, H&E-stained lung tissues 
obtained from mice treated with high-dose anti–PD-1 NPs showed severe interstitial pneumonitis (Figure 
3A). Immunofluorescence staining of  the lung additionally revealed extensive infiltration of  CD3+ T cells 
and CD11b+ macrophages (Figure 3B). Moreover, lymphocytic infiltrates were observed in the liver, heart, 
and pancreas of  these mice (Supplemental Figure 2).
We sought to evaluate the functional role of  the spleen in the high mortality rate of  animals treated 
with high-dose anti–PD-1 NPs (Figure 3C). Splenectomized mice were treated with high-dose anti–PD-1 
NPs as outlined above. Compared with the treated group of  WT mice, the splenectomized mice experi-
enced a markedly lower death rate of  25% (1 of  4 treated mice). Considering that lymph nodes could also 
be sites of  immune activation in these mice, we performed the same high-dose treatment regimen in LT-α–/– 
mice, which notably lack lymph nodes (30). In LT-α–/– mice, we also noted a decreased death rate of  25% 
(1 of  4 treated mice). To address the collective effect of  spleen and lymph nodes on the pathogenesis of  
anti–PD-1 toxicity, we administered a high dose of  anti–PD-1 NPs to splenectomized LT-α–/– mice. None 
of  these mice died within 30 days of  observation (5 of  5 treated mice).
Thereafter, we assessed if, indeed, the PD-1 pathway mediated the elevated death rate associated with 
high-dose anti–PD-1 NPs by treating PD-1–/– mice with anti–PD-1 NPs. No death was observed in this 
group of  mice, either (5 of  5 treated mice). These data show that SLTs play a vital role in the pathogenesis 
of  anti–PD-1 NP–mediated organ toxicity and that the death seen in mice receiving treatment is due to 
engagement of  the PD-1 pathway.
Overproduction of  cytokines, referred to as cytokine storm, is known to be a key pathologic feature 
of  immune overactivation associated with the use of  immunetherapeutics (31, 32). To examine the pro-
duction of  inflammatory cytokines in the anti–PD-1 NP–treated mice, we treated the C57BL/6 mice 
with a high dose of  anti–PD-1 NPs every other day for 10 days. Then, the mice were sacrificed 1 hour 
after the last injection, and their serum was assessed by multiplex assays. Luminex data showed that 
mice treated with high-dose anti–PD-1 NPs had higher levels of  inflammatory Th1 cytokines — spe-
cifically IFN-γ, IL-2, and TNF-α — as compared with the mice in anti–PD-1 mAb– or vehicle-treated 
groups (Figure 4A). Data for other cytokines are shown in Supplemental Figure 3.
Next, we sought to study the activation status of  splenic T cells in mice that received high-dose 
anti–PD-1 NPs, anti–PD-1, or vehicle. Here, we observed an increase in splenic CD4+CD69+ T cells 
in mice treated with anti–PD-1 NPs, as compared with the anti–PD-1 mAb– or vehicle-treated mice. 
Also, the population of  effector memory CD4+ T cells (CD44hiCD62Llo) was significantly higher in the 
spleens of  the mice treated with anti–PD-1 NPs, as compared with the control groups. No difference 
in the frequency of  Tregs was observed between the 3 groups (Supplemental Figure 4A). Moreover, 
a higher percentage of  CD4+ T cells expressed IFN-γ in the spleens of  mice receiving anti–PD-1 NPs 
in comparison with the mice in the vehicle-treated group (Figure 4B). Flow cytometric analysis of  
splenocyte from C57BL/6 mice indicated that splenocytes from anti–PD-1 NP–treated mice had a sig-
nificantly higher proportion of  CD8+CD69+ cells compared with the splenocytes from vehicle-treated 
mice. No difference was observed in the proportion of  CD8+CD44hi CD62Llo effector memory and 
CD8+ IFN-γ+ T cells in the splenocytes from anti–PD-1 NP–treated mice compared with anti–PD-1 
and vehicle-treated mice (Supplemental Figure 4B).
Anti–PD-1 NPs improve the efficacy of  anti–PD-1 in suppression of  murine melanoma tumor. To characterize and 
study the functionality and efficacy of anti–PD-1 NPs in the treatment of melanoma, we used the B16-F10 
mouse model. Notably, to minimize the side effects of anti–PD-1 NPs in the B16-F10 melanoma tumor–bear-
ing mice, we decreased the dosage (1.8 μg anti–PD-1 mAb per 100 μl of  NPs injection/mouse) and the frequen-
cy of injections (2×week). Lowering the cumulative dosage of anti–PD-1 NPs prevented toxicity, as demon-
strated by the lack of difference in the number of infiltrating lymphocytes in the tissues of mice treated with 
anti–PD-1 NPs, as compared with those of mice treated with anti–PD-1 or vehicle (Supplemental Figure 5).
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To study whether prophylactic treatment of melanoma with anti–PD-1 NPs resulted in a decrease in tumor 
growth, we treated mice 1 day prior to inoculation of melanoma cells. As shown in Figure 5A, treatment with 
anti–PD-1 NPs resulted in a reduction in tumor size, as compared with treatment with an equivalent dose of  
anti–PD-1 mAb, empty NPs, or vehicle. The average tumor size for vehicle-, empty NP–, anti–PD-1–, and 
Figure 3. Administration of high-dose anti–PD-1 NPs results in significant T cell activation and death. (A) Light micrograph of H&E-stained lung 
tissue from anti–PD-1 NP–treated mice reveals higher cellular infiltration, indicative of interstitial pneumonitis, as compared with the lungs from anti–
PD-1–treated and naive mice. These images are representative of 2 sections of 3–4 different mice in each group. (B) Immunofluorescence micrograph 
of lung tissue showing extensive infiltration of CD3+ T cells and CD11b+ macrophages. Scale bars: (from top to bottom) 2,000 μm, 500 μm, and 100 μm. 
These images are representative of 3 sections of 3–4 different mice in each group. (C) Kaplan-Meier survival curves for the C57BL/6 and LT-α–/– mice 
with and without splenectomy, as well as PD-1–/– mice following high-dose anti–PD-1 NPs treatment every other day for the lifespan of the study (3.6 
μg anti–PD-1 mAb per 100 μl of NPs injection/mouse). C57BL/6 WT mice had a higher rate of mortality compared with splenectomized C57BL/6 mice, 
LT-α–/– mice, and PD-1–/– mice (n = 4–7 mice/group). *P<0.05, calculated by the log-rank test (Mantel-Cox).
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anti–PD-1 NP–treated mice were 915 (± 397), 814 (± 553), 1,111 (± 961), and 322 (±2 89) mm3 respectively, 17 
days following tumor inoculation (n = 5 mice/group).
Next, we assessed the efficacy of  the anti–PD-1 NPs in the treatment of  established tumors. Mice 
were implanted with melanoma tumor cells, and the tumor size was allowed to reach to 25-30 mm3. Then, 
the mice were randomized into different groups and treatment began with injecting of  different therapeu-
tics. Twenty-four days following tumor inoculation, the average tumor size for the vehicle-, empty NP–, 
anti–PD-1–, and anti–PD-1 NP–treated mice were 1,242 (± 133), 1,385 (± 388), 802 (± 348), and 580 (± 
208) mm3, respectively, (n = 6–7 mice/group). Treatment with anti–PD-1 NPs decelerated tumor growth 
significantly in comparison with treatment with empty NPs or vehicle. Though there was a trend toward 
improved efficacy, no statistical difference was found between the tumor size of  anti–PD-1– and anti–PD-1 
NP–treated mice (Figure 5B). Additionally, the mean tumor growth inhibition percentage, measured 24 
days following the inoculation of  melanoma, was higher in the mice that received anti–PD-1 NPs (53.24%), 
as compared with the mice that received the same dosage of  anti–PD-1 (35.42%). Linear regression was 
used to compare the slopes of  the 2 groups, which revealed average tumor growth slopes 34 ± 5.5 and 23 ± 
4 for mice treated with anti–PD-1 and anti–PD-1 NPs, respectively (P < 0.01).
The potential mechanisms by which anti–PD-1 NPs evoke potent antitumor effects were also studied. Mel-
anoma tumor–bearing mice treated with anti–PD-1 NPs, anti–PD-1, or vehicle were sacrificed 17 days after 
tumor inoculation. Splenocytes were subjected to flow cytometry to assess the relative abundance of activated 
T cells in the different groups. Anti–PD-1 NP–treated mice exhibited significant increases in the percentages 
of effector splenic CD4+CD44hiCD62Llo and CD8+CD44hiCD62Llo T cells compared with mice treated with 
anti–PD-1 or vehicle (Figure 6A). Moreover, significantly higher proportions of both CD4+ and CD8+ T cells in 
Figure 4. Cytokine profile and T cell immune activation status of mice following treatment with high-dose anti–PD-1 NPs. Mice received anti–PD-1 NPs 
every other day for 10 days. (A) Luminex analysis indicating a significant increase in Th1 cytokine levels in plasma of mice treated with anti–PD-1 NPs. (B) Flow 
cytometric analysis from C57BL/6 mice indicating that the splenocytes from anti–PD-1 NP–treated mice had a significantly higher proportion of CD4+CD69+, 
CD4+CD44hiCD62Llo effector memory, and CD4+IFN-γ+ T cells, as compared with free anti–PD-1 (anti–PD-1) and vehicle-treated mice. The data are representative 
of 2 independent experiments. Data represent mean ± SEM (n = 3–4 mice/group). *P<0.05; **P<0.01; ***P<0.005, calculated by 1-way ANOVA.
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the spleens of mice treated with anti–PD-1 NPs had an activated CD69+ phenotype, compared with the CD4+ 
and CD8+ T cells in mice treated with anti–PD-1 or vehicle (Figure 6B). Given that IFN-γ is a critical purveyor 
of antitumor immunity, we examined the expression of IFN-γ by splenocytes, as well. Higher percentages of  
CD4+ T cells in the spleen of mice treated with anti–PD-1 NPs expressed the Th1 cytokine IFN-γ, as compared 
with those from mice that received anti–PD-1 or vehicle (Figure 6C). Treatment with anti–PD-1 NPs, however, 
did not significantly alter the percentage of CD8+ T cells expressing IFN-γ in the spleen.
Additionally, a higher percentage of  CD11c+CD86+ DCs was observed in the spleens of  anti–PD-1 
NP–treated mice, as compared with those from the mice that received anti–PD-1 or vehicle (Figure 6D). 
This finding corroborates our results discussed previously, which demonstrated that in vitro treatment with 
anti–PD-1 NPs resulted in the activation of  CD11c+ DCs (Figure 1, F–H).
We also investigated whether anti–PD-1 NPs affects the phenotype of  T cells in melanoma tumors. 
Melanoma tumors in mice treated with anti–PD-1 NPs contained a higher percentage of  CD4+ and CD8+ 
T cells, compared with the tumors in mice that received anti–PD-1 or vehicle (Figure 7, A and B). As 
shown in Figure 7C, the ratio between CD8+ T cells and CD4+CD25+FOXP3+ Tregs (CD8+/CD4+CD25+-
FOXP3+), which reflects the therapeutic efficacy of  tumor immunotherapy, was 4- to 5-fold higher in mice 
that received anti–PD-1 NPs versus anti–PD-1 or vehicle.
Discussion
Immune checkpoint blockade with anti–PD-1 agents has demonstrated impressive benefits in the treatment 
of  several cancers (33). However, the toxicity associated with immune checkpoint inhibitors, such as anti-
PD-1/PD-L1 therapeutics, has grown to be a significant medical problem (7, 34). These complications, 
such as pneumonitis, have been described in nearly 10% of  patients who receive anti–PD-1/PD-L1 therapy, 
Figure 5. Anti–PD-1 NPs decreases tumor growth in a B16-F10 murine melanoma model. (A) In vivo treatment plan and tumor growth kinetics in a pro-
phylactic model. C57BL/6 mice received the treatment 1 day prior to inoculation of B16-F10 melanoma cells, and the sizes of the tumors were compared at 
day 17 with Student’s t test (n = 5 mice/group). Data represent mean ± SEM. (B) In vivo treatment plan and tumor growth kinetics in a therapeutic model. 
Treatment started at 10 days after B16-F10 melanoma cell inoculation in C57BL/6 mice (n = 6–7 mice/group), and the sizes of the tumors were compared at 
day 24 with Student’s t test. Data represent mean ± SEM. *P<0.05; **P<0.01; ***P<0.005, calculated by t test.
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either alone or in combination with other drugs (7). Moreover, in addition to being frequent, these compli-
cations can be lethal.
The recent advent of  engineered mAb has significantly changed the course of  refractory diseases. How-
ever, several limitations impede their full utility. For instance, large antibodies might have poor tissue pen-
etration. Strategies using mAb often rely on several injections of  mAb, which could increase the cost and 
may raise issues with patient compliance. Nanotechnology improves not only the pharmacokinetics of  
the therapeutic payload, but it also allows for site-specific targeted drug delivery (35–37). Using NPs can 
enhance tissue penetration and the capacity for intracellular delivery of  antibodies. The NPs that have been 
designed herein have strong potential for clinical translation, as they are prepared from FDA-approved 
PEG and PLGA polymers. Physical characterization of  our NPs demonstrated a spherical morphology 
with an average size of  ~150 nm and an encapsulation efficacy of  26.2% ± 3%. In vitro release kinetics of  
anti–PD-1 mAb from the NPs revealed sustained release of  anti–PD-1 over time. Using centrifugal filter 
units significantly reduced the nonspecific binding of  the antibody to the surface. Hence, this method mark-
edly reduced the burst release and allowed for controlled, sustained release of  anti–PD-1 mAb over time.
As SLTs are the primary sites for immuneactivation, circulating immune cells migrate to the spleen, 
where they can encounter antigens presented by APCs, such as DCs. Following activation, T cells infiltrate 
the tumor site and can effectively kill tumor cells. Our goal was to develop a simple and clinically feasible 
approach that would allow delivery of  anti–PD-1 to the SLTs.
The spleen is a major SLT particularly well perfused by blood (~350 ml/min), which facilitates the 
delivery of  the payload. Importantly, the marginal zone that surrounds the white pulp region of  the spleen 
contains numerous APCs, including DCs. As such, the immune response against tumor antigens in the 
spleen can be enhanced by tipping the homeostasis either toward immunoregulatory and suppressive cells 
or immunogenic effector cells. Of  note, in addition to immune activation, peripheral tolerance toward anti-
gens (including tumor antigens) can originate in and develop from the spleen (23, 38, 39).
Previous studies have established the propensity of  NPs to become sequestered in the spleen; however, 
to improve the efficacy of  targeted delivery of  NPs, meaningful efforts are underway to reduce splenic 
trafficking (40, 41). In this study, on the contrary, we hypothesized that optimization of  the payload of  
anti–PD-1 delivered to the DCs of  the spleen would increase its capacity to suppress tumor growth. Martin 
et al. were the first to show that allogeneic splenocytes cross-linked with ethylene carbodiimide induced 
splenic tolerance (42). Leuschner et al. have shown that delivery of  siRNA that targets CCR2-express-
ing monocytes could abrogate inflammatory responses in atherosclerotic plaques (41). Others have also 
demonstrated that PLGA NPs deliver tumor-specific antigens to DCs in a protected and sustained-release 
manner (43–45). In this study, we demonstrated that the delivery of  anti–PD-1 within PLGA NPs facilitat-
ed its uptake by DCs and enhanced the effector T cell response in the SLTs.
In our study, WT mice treated with high-dose anti–PD-1 NPs exhibited a high rate of  mortality. His-
topathological analysis of  organs from these mice revealed massive infiltration of  immune cells, which 
was especially prominent in the lungs and corroborated the reports of  severe toxic effects of  anti–PD-1 
mAb drugs (46–48). Removal of  the spleen reduced the rate of  death in these animals significantly. As 
the lymph node is also a major component of  SLTs, we additionally showed that LT-α–/– mice, in which 
lymph nodes are absent, were also protected against death. Notably, removal of  the spleen in LT-α–/– 
mice completely protected these mice from death. The observation that PD-1–/– mice were also protected 
(Figure 3C) implies that the blockade of  the PD-1 signaling pathway is similarly essential for the protec-
tion from death. Results provided here have significant clinical implications, given the dramatic increase 
in the use of  checkpoint inhibitors and the rise in the incidence of  toxicities associated with their use.
In line with the above observation, to decrease the toxicity of  anti–PD-1 NPs, we were able to lower the 
concentration of  anti–PD-1 and decrease the frequency of  injections. No noticeable difference in infiltrat-
ing lymphocytes was observed in the nonlymphoid tissues of  mice that received a low dose of  anti–PD-1 
NPs, compared with the mice that received vehicle or anti–PD-1.
Figure 6. T cell profile of the spleens from anti–PD-1 NP–treated B16-F10 melanoma tumor–bearing C57BL/6 mice at day 17 following tumor cell inoc-
ulation. (A and B) The spleens of mice in the anti–PD-1 NP–treated group had higher percentages of CD4+ and CD8+ effector memory T cells, CD4+CD69+ T 
cells, and CD8+CD69+ T cells in comparison with anti–PD-1– or vehicle-treated mice. (C) The percentage of CD4+IFN-γ+ T cells was significantly higher in the 
spleens of mice treated with anti–PD-1 NPs than in those of mice receiving free anti–PD-1 (anti–PD-1) or vehicle. (D) A significantly higher percentage of 
CD11c+CD86+ cells was observed in the spleens of mice treated with anti–PD-1 NPs in comparison with those of mice treated with free anti–PD-1 or vehicle. 
Data are presented as mean ± SEM (n = 3 mice/group). *P<0.05; **P<0.01, calculated by 1-way ANOVA.
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Furthermore, we evaluated the effect of  anti–PD-1 NPs in B16-F10 mice, a highly stringent animal 
model of  melanoma. Our data exhibited that treatment with anti–PD-1 NPs in both the prophylactic and 
therapeutic treatment modalities demonstrated efficacy in reducing tumor growth rate. The cumulative dos-
age of  anti–PD-1 administered via our NP (10.8 μg and 9 μg for the prophylactic and therapeutic modal-
ities, respectively) was significantly lower than the amount of  anti–PD-1 (2,200 μg) used in a previous 
experiment, which showed no therapeutic effect (49).
Mechanistically, in addition to the general activation of  T cells, the shifting of  differentiated T cells 
toward a CD4+ Th1 cell phenotype has been shown to protect against tumors through the production of  
IFN-γ. Consistent with this mechanism, we observed a high number of  IFN-γ–producing CD4+ T cells in 
the spleens of  the anti–PD-1 NP–treated mice.
In addition to its cytotoxic effect, IFN-γ has recently been shown to induce fragility of  Tregs (50). 
Whether IFN-γ affected the fragility of  Tregs in our model remains to be studied. Although IFN-γ has been 
shown to promote tumor development in certain tumor models (51, 52), our data suggest that IFN-γ can 
modulate the immune response in favor of  an antitumor effect. Furthermore, the proportion of  effector 
memory CD8+ T cells in the spleen of  mice receiving anti–PD-1 NPs was increased, and these cells were 
highly activated (CD8+CD69+), which likely contributed to the enhanced clearance of  the tumor in our 
model. The activation of  cytotoxic T cells (CD8+CD69+) by treatment with anti–PD-1 NPs can also be 
attributed to IFN-γ signaling, as another tumor model has demonstrated (53). While we show that absence 
of  lymph nodes reduces the mortality rate, future studies are required to assess the microenvironment of  the 
draining lymph nodes for immune activation and drug delivery (54). Interestingly, the local populations of  
CD4+ and CD8+ T cells at the tumor site were increased in the mice that received anti–PD-1 NPs, but the 
activation status of  these cells did not change. We observed a trend toward an increased ratio of  CD8+ T cells 
to CD4+CD25+FOXP3+ Tregs in the tumor following treatment with anti–PD-1 NPs. This ratio determines 
the balance between the proinflammatory (CD8+) versus antiinflammatory (CD4+CD25+FOXP3+) response 
against the tumor. The increased ratio observed in our study suggests a more dominant role of  CD8+ T cells 
Figure 7. T cell profile of the tumors from anti–PD-1 NP–treated B16-F10 melanoma tumor–bearing C57BL/6 mice at 
day 17 following tumor cell inoculation. (A and B) Analysis of CD4+ T cells and CD8+ T cells showing highest percentages 
of these cells in the melanoma tumors of mice treated with anti–PD-1 NPs. (C) The ratio of CD8+/CD4+CD25+FOXP3+ in 
the melanoma tumors was higher in mice that received anti–PD-1 NPs versus free anti–PD-1 (anti–PD-1) or vehicle. Data 
are presented as mean ± SEM (n = 3 mice/group). *P<0.05; calculated by 1-way ANOVA.
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in enhancing the clearance of  the tumor. A higher ratio of  CD8+ to CD4+CD25+FOXP3+ T cells has also 
been shown to be a prognostic marker for the survival of  cancer patients (55). The finding that our NPs traf-
fic to the tumor following systemic delivery suggests that the delivery of  anti–PD-1 directly to the tumor may 
also have resulted in an intensification of  local antitumor immunity (56). The lack of  discernable impacts 
on tumor-infiltrating immune cells could be due to the timing at which we investigated the tumor microen-
vironment. Additionally, much of  the antitumor effects could be due to soluble mediators or cytokines that 
are more complicated to assess than the mere enumeration of  immune cells because of  the kinetics and short 
stability of  some of  the cytokines — specifically, cytokines such as IL-2 and TNF-α are difficult to measure 
because of  their labile nature.
Tumor-derived factors suppress the full maturation of  DCs, thereby affecting their ability to process 
and present antigens (3). In contrast, mature DCs can activate CD4+ and CD8+ effector memory T cells 
in the spleen, which results in enhanced antineoplastic activities (57). APCs induce antitumor immune 
responses via efficient processing and presentation of  tumor antigens, followed by subsequent priming 
of  tumor antigen-specific T cells. These effector T cells participate in the eradication of  the tumor at the 
tumor site (58). We observed high expression of  the positive costimulatory molecule CD86 on the DCs in 
the spleens of  anti–PD-1 NP–treated mice, suggesting an improvement in the maturation and activation 
of  these cells. CD86+ DCs can present tumor antigens more effectively to prime antitumor cytotoxic and 
helper T cells, as has been reported earlier (59).
Failure of  any of  these steps suppresses antitumor immune responses, and therefore the interest in 
understanding these processes both under normal and pathophysiological conditions has intensified.
Collectively, our study shows that the administration of  anti–PD-1 NPs can lead to antitumor immu-
nity in the murine B16-F10 melanoma model. Potential mechanisms for this superior antitumor immune 
response mediated by anti–PD-1 NPs remain to be elucidated. It is likely that the uptake of  anti–PD-1 
NPs by CD11c+ DCs enhances the maturation and activation of  DCs. We show enhanced maturation and 
activation by the increased expression of  costimulatory receptors, including CD40, CD80, and CD86 in 
DCs. Once activated, the DCs can, in turn, activate effector T cells, thereby inducing an immune response 
against cancer cells. Our data demonstrate that the effective dosage of  anti–PD-1 for evoking antitumor 
immunity in a murine melanoma cancer model could be reduced significantly by incorporating this thera-
peutic agent in NPs. This dose reduction was facilitated by a focused delivery of  the NPs and their uptake 
by APCs in the SLTs. Our study demonstrates that treatment with anti–PD-1 NPs reduced tumor growth 
rate significantly in a murine melanoma model. Lastly, the anti–PD-1 mAb may promote the interaction 
of  NPs with immune cells and internalization of  the NPs. Such an interaction may increase the expression 
of  adhesion molecules, enhancing the adhesive capacity of  effector immune cells with target tumor cells.
In summary, we demonstrate the potential of  an NP-based platform that delivers anti–PD-1 to the 
spleen to further enhance antitumor immunity in a murine melanoma model. The use of  this platform sig-
nificantly reduces the need for treatment with high dosage of  anti–PD-1. Our data highlight the importance 
of  SLTs in promoting antitumor immunity and in increasing the toxicity of  anti–PD-1.
Methods
Animal studies. Female C57BL/6, PD-1–/– (B6. Cg-Pdcd1tm1.1Shr/J), LT-α–/– (B6.129S2-Ltatm1Dch/J), and 
BALB/c mice (7–9 weeks old, body weight of  18–21 g) were purchased from The Jackson Laboratory.
Synthesis and characterization of  NPs. PLGA-based NPs were prepared using a double-emulsion evapo-
ration method. Briefly, 4.2 mg of  mPEG-PLGA (Methoxy Poly[ethylene glycol]-b-Poly[D,L-lactide-co-gly-
colide]); Mw 5,000:30,000 Da; 50:50 LA:GA (w:w) copolymer (AK102, Polyscitech) was dissolved in ethyl 
acetate (Thermo Fisher Scientific) to form the oil phase. An aqueous solution of  70 μg of  anti–PD-1 mAb 
(Purified anti–mouse CD279 [PD-1] antibody [RMP1-14, BioLegend] or APC anti–mouse CD279 [PD-1] 
antibody [29F.1A12, BioLegend]) were added to the oil phase and emulsified by sonication for 60 seconds. 
The emulsified solution was added dropwise to 3 ml of  1% aqueous polyvinyl alcohol solution (PVA, Mw 
~31,000, MilliporeSigma) on high vortex and sonicated for 60 seconds. Then, the mixture was added to a 
0.25% PVA aqueous solution (20 ml) and stirred continuously at room temperature for 3 hours to permit 
solidification of  the NPs and evaporation of  ethyl acetate. The NPs were concentrated by centrifugation at 
2,700 g, using Amicon Ultra-15 centrifugal filter units (MWCO 100 kDa, MilliporeSigma). Every 10 min-
utes, centrifugation was halted, and more NPs were added to the top of  the filter unit. Following achieve-
ment of  the desired concentration, the NPs were washed twice with Dulbecco’s phosphate-buffered saline 
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(DPBS) (Mediatech Inc.). A 0.5 ml suspension of  NPs was transferred to a new tube designated as the high 
dose. This suspension was diluted in half  with DPBS to create the low-dose NPs.
Fluorescently labeled NPs were synthesized from mPEG-PLGA copolymer and IRDye 800CW 
Carboxylate (LI-COR) or CF660R, Maleimide (MilliporeSigma) by nanoprecipitation. Briefly, 5 mg of  
the polymer was dissolved in acetone. Then, the dye was dissolved in methanol and added to the poly-
mer solution. This solution (1.0 ml) was added dropwise into a 0.015% PVA aqueous solution (10 ml) 
under vigorous stirring to formulate IR800 NPs or CF660 NPs. The NP suspension was stirred uncov-
ered for 3 hours at room temperature in a chemical hood to evaporate the organic solvent completely. 
Then, the NPs were concentrated and washed, as described above.
The size distribution of  anti–PD-1 NPs was determined using Malvern Zetasizer Nano ZS. Measure-
ments were made in triplicates at room temperature. The morphology of  NPs was assessed with transmis-
sion electron microscopy (TEM, JEOL 1200EX).
In vitro release studies of  anti–PD-1 mAb from NPs. To study the release of  anti–PD-1 mAb from NPs, the 
NPs were loaded onto the filter in an ultrafiltration centrifuge tube, and the bottom of  the tube was filled 
with DPBS. Then, the samples were incubated in an orbital shaker (Forma; Thermo Fisher Scientific) at a 
speed of  200 rpm at 37°C. At predetermined intervals, 200 μl of  DPBS was removed from the bottom of  
the tube for analysis, and 200 μl of  fresh DPBS was added to maintain a constant volume. The concentra-
tion of  released antibody was determined by ELISA. ELISA plates (96-Well Flat-Bottom Immuno Plate, 
MaxiSorp, Nonsterile PS, Thermo Fisher Scientific) were coated overnight with mouse rPD-1 (ACRO Bio-
systems, M5228), washed 3 times with DPBST, and blocked with 1 mg/ml BSA in DPBST overnight, fol-
lowed by 3 washes. Then, NP samples collected at the specified time points and anti–PD-1 mAb standard 
samples (with known concentration) were incubated in the precoated wells for 1 hour at 37°C, followed by 
4 washes with DPBS+Tween20 (DPBST). The plates were incubated with 0.25 μg/ml of  HRP-conjugated 
goat anti–rat IgG antibody (MilliporeSigma, AP 136P) for 1 hour, washed 4 times with DPBST, and devel-
oped with the Tetramethylbenzidine Substrate Solution (TMB, eBioscience, 00-4201-52) as per manufactur-
er’s instructions. Absorption at 450 nm was measured on a plate reader (VersaMAX, Molecular Devices). 
Empty NPs were used as the base, and the actual concentration of  anti–PD-1 mAb was calculated by 
comparing the results to a standard curve.
T cell proliferation assay and assessment of  activation markers of  DCs. The capacity of  DCs to induce acti-
vation of  T cells following treatment with anti–PD-1 NPs was assessed using an allogeneic MLR assay. 
Murine CD11c+ DCs (C57BL/6 mice) and CD3+ T cells (BALB/c mice) were isolated from spleens using 
magnetic beads conjugated with anti–mouse CD11c (Miltenyi Biotec) and the EasySep Mouse T Cell Iso-
lation Kit (Stemcell Technologies), respectively.
CD11c+ DCs (150,000 cells/well) were cultured in complete RPMI-1640 medium (Lonza), supple-
mented with 10% FBS (Gemini Bio-Products), 1% penicillin/streptomycin (Corning), and 1% L-Gluta-
mine (Corning) and were treated with free anti–PD-1 mAb (anti–PD-1), anti–PD-1 NPs, or empty NPs. 
After an incubation period of  24 hours, a portion of  the CD11c+ DCs was analyzed for the presence of  
activation markers by flow cytometry. The remainder of  the CD11c+ DCs was washed with DPBS, and 
allogeneic CD3+ T cells (300,000 cells/well) were added to these cells. The cells were incubated together 
for 48 hours at 37°C in a humidified atmosphere containing 5% CO2. Then, the cultured cells were labeled 
with [3H]-Thymidine (0.25 μCi per well) for an additional 16 hours to measure T cell proliferation.
To study the potential role of  DCs play in the release of  anti–PD-1 mAb following the uptake of  
NPs, 150,000 DCs cells/well were cultured in complete RPMI-1640 medium and treated with APC-labeled 
anti–PD-1 NPs. After 1 hour of  incubation, CD11c+ DCs were washed twice with DPBS, and CD3+ T cells 
(450,000 cells/well) were added to these cells. These cells were incubated together for 6 hours at 37°C in a 
humidified atmosphere containing 5% CO2. Then, the T cells were examined by flow cytometric analysis.
Tumor implantation. B16-F10 murine melanoma cells were cultured in complete RPMI-1640 medium. 
Cells in exponential growth phase were harvested from culture, washed twice with sterile DPBS, counted, 
and resuspended in DPBS. For the prophylactic model, 200,000 murine B16-F10 melanoma cells were 
grafted s.c. into both flanks of  C57BL/6 mice. For the therapeutic model, 25,000 B16-F10 murine melano-
ma cells were inoculated s.c. into the right flanks of  C57BL/6 mice. Ten days after tumor cell inoculation, 
mice with tumors around 25–30 mm3 in size were randomized into different groups and given specified 
treatments: 100 μl of  anti–PD-1 NPs suspension (1.8 μg anti–PD-1 mAb loaded in 100 μl of  anti–PD-1 
NPs), empty NPs, free anti–PD-1 (1.8 μg anti–PD-1 mAb in DPBS), or vehicle (DPBS). From each group, 
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3–4 mice were sacrificed 17 days following inoculation, and the tumors and spleens were collected for flow 
cytometric analyses. Antitumor activity was evaluated in terms of  tumor volume (V), in which l and w are, 
respectively, the larger and smaller diameters of  the tumor as measured by a digital caliper, defined as
     (Equation 1)
The mean tumor growth inhibition (%TGI), in which Vc and Vt are, respectively, the sizes of  the control 
and treated groups at the end of  the study (60) was calculated according to the formula:
          (Equation 2)
Tumor growth was assayed as described above until the experimental endpoint was reached or when exces-
sive tumor burden or disease state required protocol-stipulated euthanasia.
In vivo trafficking of  NPs. To study the trafficking of NPs, B16-F10 melanoma tumor-bearing mice (n = 3–4/
group) were anesthetized via inhalation of isoflurane/oxygen and IR800 NPs were administered i.v. Trafficking 
of IR800 NPs was studied using a UVP iBOX Explorer Imaging Microscope (UVP) equipped with a 750–780 
nm excitation filter and an 800 nm long-pass emission filter. For live imaging, mice were anesthetized and placed 
inside the dark box in prone position. For ex vivo imaging, mice were sacrificed via CO2 inhalation and cervical 
dislocation. Tumors and spleens were harvested for imaging.
Splenectomy. C57BL/6 and LT-α–/– mice were anesthetized via inhalation of  isoflurane/oxygen. Then, 
a 1-cm incision was made in the skin on the left upper abdomen, and the spleen was removed. The splenic 
artery and vein were tied, and the abdominal wall was closed with a 6-0 silk running suture.
Flow cytometry. To prepare single-cell suspensions from spleens, spleen was minced into small frag-
ments in DPBS and placed onto a 70-μm cell strainer (BD Falcon) attached to a 50-ml conical tube. Next, 
fragments of  the spleen were pressed through a strainer using the plunger end of  a syringe and washed 
through the strainer with excess DPBS. Next, the cell suspension was centrifuged at 550 g for 5 minutes. 
The supernatant was discarded, and the cell pellet was resuspended in 1 ml ACK lysis buffer (Lonza) for 2 
minutes. DPBS (30 ml) was added to dilute the lysis buffer, and the cell suspension was centrifuged again. 
After discarding the supernatant, the cell pellet was resuspended in RPMI-1640 to a concentration of  1 × 
107 cells/ml. The same protocol was used for preparing single-cell suspensions from melanoma tumors.
Single-cell suspensions were plated in 96-well round-bottom plates (Corning) for intracellular cytokine 
staining and 96-well V-bottom plates (Corning) for surface and intracellular transcription factor staining. For 
intracellular IFN-γ staining, the single-cell suspensions were stimulated with phorbol 12-mystirate 13-acetate 
(100 ng/ml, MilliporeSigma), ionomycin (1 μg/ml, MilliporeSigma), and GolgiStop protein transport inhib-
itor (BD Biosciences) at 37°C for 4 hours prior to staining. Then, the cells were stained with Fixable Viability 
Dye (eBioscience Fixable Viability Dye eFluor450) diluted 1:1,000 μl in DPBS for 30 minutes at °C. Next, 
the cells were washed with FACS buffer (DPBS + 2% FBS + 1 mM EDTA + 0.1% sodium azide) and incu-
bated for 25 minutes at 4°C with fluorochrome-conjugated murine antibodies against CD3 (17A2), CD8a 
(53-6.7), CD4 (GK1.5), CD62L (MEL-14), CD44 (IM7), CD25 (PC61), CD69 (H1.2F3), PD-1 (RMP1-30), 
CD45 (30-F11), CD45R/B220 (RA3-6B2), F4/80 (BM8), CD11b (M1/70), CD11c (N418; eBioscience), 
CD40 (3/23), CD80 (16-10A1; eBioscience), and CD86 (GL1 [RUO]; BD Biosciences). Antibodies were 
purchased from BioLegend, unless otherwise stated. All cell-surface antibodies were diluted 1:300 μl in 
FACS buffer. The cells were permeabilized using the eBioscience Intracellular Fixation and Permeabili-
zation Buffer Set (Thermo Fisher Scientific) for 30 minutes at 4°C. Next, they were incubated with fluoro-
chrome-labeled intracellular antibodies against IFN-γ (XMG1.2) and FoxP3 (MF-14) diluted 1:300 μl in 
permeabilization buffer. Cells were washed once with permeabilization buffer and fixed in FACS buffer + 
1% formalin. Flow cytometry was performed with a BD FACSCanto II flow cytometer (BD Biosciences). 
Analysis of  flow cytometry data was performed by FlowJo (FlowJo).
Luminex assay for quantification of  cytokines. After sacrificing mice, blood was obtained and centri-
fuged at 2,000 g for 10 minutes, and serum samples were collected. The concentration of  cytokines 
was detected in these samples using the MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic 
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Kit (MilliporeSigma), as per manufacturer’s instructions. Median fluorescence intensity was measured 
by a Luminex 200 IS instrument and analyzed using the logistic curve-fitting method to determine 
cytokine concentrations.
Histology and immunofluorescence imaging. To study the cellular uptake of  NPs in vitro, cultured spleno-
cytes were incubated with fluorescently labeled NPs for 3 hours at 37°C and washed 3 times with DPBS. 
The samples were then stained with FITC-labeled anti-CD11b (M1/70; BioLegend), anti-CD11c (N418; 
eBioscience), and anti-F4/80 antibodies (BM8; BioLegend), as well as mounting medium with DAPI 
(VECTASHIELD, Vector Laboratories Burlingame).
For H&E staining, tissues were fixed in 10% formalin solution and embedded in paraffin blocks. Sec-
tions were cut and stained with H&E by conventional techniques.
For immunofluorescence imaging, mice tissues were flash-frozen in OCT compound (Tissue-Tek, 
Thermo Fisher Scientific) and cut into 8-μm sections with a cryomicrotome. Sections were fixed in cold 
acetone for 10 minutes and then blocked with 3% BSA for 30 minutes at room temperature. Next, the 
sections were incubated overnight at 4°C with primary antibodies: anti-CD3 antibody (SP7, Abcam; 
or 17A2, eBioscience) and anti-insulin antibody (Abcam). The sections were then incubated with sec-
ondary antibodies: AlexaFluor 488 goat anti–rabbit IgG (catalog A27034, Thermo Fisher Scientific), 
AlexaFluor 594 goat anti–rat IgG (catalog A-11007, Thermo Fisher Scientific), and AlexaFluor 594 
goat anti–rabbit IgG (catalog A-11037, Thermo Fisher Scientific) for 30 minutes at room temperature. 
FITC-conjugated anti-CD11b (M1/70; BioLegend) antibody was used for CD11b+ staining. Finally, the 
slides were washed with DPBS for 5 minutes, stained with DAPI, and coverslipped.
Data Availability. All data generated or analyzed during this study are available from the corresponding 
author on reasonable request.
Statistics. A 2-tailed Student’s t test or 1-way ANOVA was used to determine statistical significance 
between 2 groups and several groups, respectively. Differences in survival in each group were determined 
using the Kaplan-Meier method, and the overall comparisons of  slopes were carried out using linear regres-
sion model (GraphPad Prism 5.0). Data represent means ± SEM. *P<0.05; **P<0.01; ***P<0.005.
Study approval. All animal experiments were approved and performed in accordance with the guidelines 
and regulations of  the IACUC of  the Brigham and Women’s Hospital and Harvard Medical School in 
Boston, Massachusetts, USA.
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